Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG@PLTm
- Development stage
- Preclinical
- Lead developer
- Nantong University
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
BCG@PLTm is an autonomously propelled, urea-powered platelet-derived nanomotor (PLTm) encapsulating Bacillus Calmette-Guérin (BCG), developed for the treatment of immunotherapy-refractory bladder cancer. The nanomotor utilizes the decomposition of urea in urine to drive active penetration through the dense extracellular matrix (ECM) of bladder tumors, overcoming the stromal barrier that typically limits intravesical BCG therapy. Mechanistically, BCG@PLTm restores the expression of death-associated protein like 1 (DAPL1), which reverses pathological ECM stiffening and alleviates immune exclusion, thereby reactivating the infiltration of cytotoxic T-cells. Preclinical studies in orthotopic mouse models have demonstrated significant tumor growth inhibition (rate > 90%) and a favorable safety profile.
- Other names
- BCG + PLTmurea-powered platelet nanomotorplatelet-derived nanomotor encapsulating BCG
02
Targets
DAPL1 (Death-associated protein-like 1)
Beyond the preview
Go deeper on BCG@PLTm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG@PLTm.